´ëÇѳ»ºÐºñÇÐȸ ºÎ¿ï°æÁöȸ 11¿ù Á¤±âÁý´ãȸ : 2023-11-21
±³À°ÀÏÀÚ : 2023-11-21
±³À°Àå¼Ò : ºÎ»ê·Ôµ¥È£ÅÚ 41Ãþ »çÆÄÀ̾î·ë
±³À°ÁÖÁ¦ : ´ëÇѳ»ºÐºñÇÐȸ ºÎ¿ï°æÁöȸ 11¿ù Á¤±âÁý´ãȸ
ÁÖÃÖ±â°ü : ´ëÇѳ»ºÐºñÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ºÎ»ê¿ï»ê°æ³²Áöȸ
´ã´çÀÚ : ÇÐȸ»ç¹«±¹
¿¬¶ôó : 051-711-6902
À̸ÞÀÏ : pukendo@naver.com
±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀÎ : 50¸í
Èñ¸ÁÆòÁ¡ : 3Á¡
Áö¿ª : ºÎ»ê±¤¿ª½Ã
±³À°½Ã°£ : 3 ½Ã°£ 0ºÐ
¼¼ºÎ¼ö°·á : 10,000¿ø
ºñ°í ºñȸ¿ø ¹× Ÿ°úÀü°øÀÇ 10,000¿ø / ºÎ¿ï°æ³»ºÐºñ´ë»çÇÐȸ ȸ¿ø, Àü°øÀÇ-¹«·á
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 11¿ù 21ÀÏ ºÎ»ê·Ôµ¥È£ÅÚ 41Ãþ »çÆÄÀ̾î·ë 19:00~19:50 CV risk ¿¹ÃøÀ» À§ÇÑ coronary artery calcium scoreÀÇ ÀÓ»óÀû È¿¿ë¼º ±¸´ëÁ¤(â¿øÆÄƼ¸¶º´¿ø)
Åä·Ð 11¿ù 21ÀÏ ºÎ»ê·Ôµ¥È£ÅÚ 41Ãþ »çÆÄÀ̾î·ë 19:50~20:00 Q & A ()
±³À°½Ã°£ 11¿ù 21ÀÏ ºÎ»ê·Ôµ¥È£ÅÚ 41Ãþ »çÆÄÀ̾î·ë 20:00~20:50 Adverse events in patients with primary hyperthyroidism with and without successful parathyroidectomy:A propensity matched comparision ÇÑÁö¹Î(â¿ø»ï¼ºº´¿ø)
Åä·Ð 11¿ù 21ÀÏ ºÎ»ê·Ôµ¥È£ÅÚ 41Ãþ »çÆÄÀ̾î·ë 20:50~21:00 Q & A ()
±³À°½Ã°£ 11¿ù 21ÀÏ ºÎ»ê·Ôµ¥È£ÅÚ 41Ãþ »çÆÄÀ̾î·ë 21:00~21:50 Multiple endocrine neoplasia 2A review ¹èÁöÇö(ºÎ»ê¾ç»ê´ëº´¿ø)
Åä·Ð 11¿ù 21ÀÏ ºÎ»ê·Ôµ¥È£ÅÚ 41Ãþ »çÆÄÀ̾î·ë 21:50~22:00 Q & A ()